New drug ESG406 enters human testing for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial is testing a new drug called ESG406 in 556 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first find a safe dose, then expand to see if the drug can shrink tumors. The main focus is on safety a…
Phase: PHASE1 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 15:56 UTC